Isoprostanes in fetal and neonatal health and disease

Free Radical Biology and Medicine

Volumn 48, Issue 2, 2010, Pages 177-188

  Belik, Jaques ^a   González Luis, Gema E ^b   Perez Vizcaino, Francisco ^c   Villamor, Eduardo ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL UNIVERSITARIO MATERNO INFANTIL DE CANARIAS   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular System; Lung; Pregnancy; Prostaglandins

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ARACHIDONIC ACID; BIOLOGICAL MARKER; FREE RADICAL; ISOPROSTANE DERIVATIVE; PROSTAGLANDIN DERIVATIVE; REACTIVE OXYGEN METABOLITE;

BIOLOGICAL ACTIVITY; CHEMICAL ANALYSIS; DRUG MECHANISM; FATTY ACID ANALYSIS; FATTY ACID BLOOD LEVEL; FATTY ACID SYNTHESIS; FETUS; FETUS DEVELOPMENT; HUMAN; LIPID MEMBRANE; LIPID PEROXIDATION; LUNG VASCULAR RESISTANCE; NEWBORN; NEWBORN PERIOD; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PERINATAL PERIOD; PREGNANCY; PRIORITY JOURNAL; REGULATORY MECHANISM; RETROLENTAL FIBROPLASIA; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SYSTEMIC VASCULAR RESISTANCE; TISSUE LEVEL; UMBILICAL CORD;

ADULT; ANIMALS; FEMALE; FETAL DEVELOPMENT; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; ISOPROSTANES; OXIDATIVE STRESS; PLACENTAL CIRCULATION; PREGNANCY; PULMONARY ARTERY; VASCULAR RESISTANCE;

EID: 73049118744     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2009.10.043     Document Type: Review

References (182)

1. Morrow J.D., Harris T.M., and Roberts L.J. Noncyclooxygenase oxidative formation of a series of novel prostaglandins: analytical ramifications for measurement of eicosanoids. Anal. Biochem. 184 (1990) 1-10
2. Morrow J.D., Hill K.E., Burk R.F., Nammour T.M., Badr K.F., and Roberts L.J. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc. Natl. Acad. Sci. USA 87 (1990) 9383-9387
3. Jahn U., Galano J.M., and Durand T. Beyond prostaglandins-chemistry and biology of cyclic oxygenated metabolites formed by free-radical pathways from polyunsaturated fatty acids. Angew. Chem. Int. Ed. 47 (2008) 5894-5955
4. Morrow J.D. The isoprostanes-unique products of arachidonate peroxidation: their role as mediators of oxidant stress. Curr. Pharm. Des. 12 (2006) 895-902
5. Taylor A.W., Bruno R.S., Frei B., and Traber M.G. Benefits of prolonged gradient separation for high-performance liquid chromatography-tandem mass spectrometry quantitation of plasma total 15-series F-isoprostanes. Anal. Biochem. 350 (2006) 41-51
6. Basu S. F2-isoprostanes in human health and diseases: from molecular mechanisms to clinical implications. Antioxid. Redox Signal. 10 (2008) 1405-1434
7. Khasawneh F.T., Huang J.S., Mir F., Srinivasan S., Tiruppathi C., and Le Breton G.C. Characterization of isoprostane signaling: evidence for a unique coordination profile of 8-iso-PGF(2alpha) with the thromboxane A(2) receptor, and activation of a separate cAMP-dependent inhibitory pathway in human platelets. Biochem. Pharmacol. 75 (2008) 2301-2315
8. Peter S.T., Scholl T.O., Schluter M.D., Leskiw M.J., Chen X., Spur B.W., et al. Oxidative stress early in pregnancy and pregnancy outcome. Free Radic. Res. 42 (2008) 841-848
9. Sies H., and Cadenas E. Oxidative stress: damage to intact cells and organs. Philos. Trans. R. Soc. Lond., B Biol. Sci. 311 (1985) 617-631
10. Belik J., Jankov R.P., Pan J., and Tanswell A.K. Peroxynitrite inhibits relaxation and induces pulmonary artery muscle contraction in the newborn rat. Free Radic. Biol. Med. 37 (2004) 1384-1392
11. Vento M., Moro M., Escrig R., Arruza L., Villar G., Izquierdo I., et al. Preterm resuscitation with low oxygen causes less Q3 oxidative stress, inflammation, and chronic lung disease. Pediatrics 124 (2009) e439-e449
12. Vento M., Aguar M., Leone T.A., Finer N.N., Gimeno A., Rich W., et al. Using intensive care technology in the delivery room: a new concept for the resuscitation of extremely preterm neonates. Pediatrics 122 (2008) 1113-1116
13. Martin R.J., Bookatz G.B., Gelfand S.L., Sastre J., Arduini A., Aguar M., et al. Consequences of neonatal resuscitation with supplemental oxygen. Semin. Perinatol. 32 (2008) 355-366
14. Pallardo F.V., Sastre J., Asensi M., Rodrigo F., Estrela J.M., and Vina J. Physiological changes in glutathione metabolism in foetal and newborn rat liver. Biochem. J. 274 Pt. 3 (1991) 891-893
15. Martin J.A., Pereda J., Martinez-Lopez I., Escrig R., Miralles V., Pallardo F.V., et al. Oxidative stress as a signal to up-regulate gamma-cystathionase in the fetal-to-neonatal transition in rats. Cell. Mol. Biol. (Noisy -le-grand) 53 Suppl. (2007) OL1010-OL1017
16. Comporti M., Signorini C., Leoncini S., Buonocore G., Rossi V., and Ciccoli L. Plasma F2-isoprostanes are elevated in newborns and inversely correlated to gestational age. Free Radic. Biol. Med. 37 (2004) 724-732
17. Friel J.K., Friesen R.W., Harding S.V., and Roberts L.J. Evidence of oxidative stress in full-term healthy infants. Pediatr. Res. 56 (2004) 878-882
18. Saugstad O.D. Bronchopulmonary dysplasia and oxidative stress: are we closer to an understanding of the pathogenesis of BPD?. Acta Paediatr. 86 (1997) 1277-1282
19. Weinberger B., Nisar S., Anwar M., Ostfeld B., and Hegyi T. Lipid peroxidation in cord blood and neonatal outcome. Pediatr. Int. 48 (2006) 479-483
20. Hardy P., Dumont I., Bhattacharya M., Hou X., Lachapelle P., Varma D.R., et al. Oxidants, nitric oxide and prostanoids in the developing ocular vasculature: a basis for ischemic retinopathy. Cardiovasc. Res. 47 (2000) 489-509
21. Ahola T., Fellman V., Kjellmer I., Raivio K.O., and Lapatto R. Plasma 8-isoprostane is increased in preterm infants who develop bronchopulmonary dysplasia or periventricular leukomalacia. Pediatr. Res. 56 (2004) 88-93
22. Yi S.L., Kantores C., Belcastro R., Cabacungan J., Tanswell A.K., and Jankov R.P. 8-Isoprostane-induced endothelin-1 production by infant rat pulmonary artery smooth muscle cells is mediated by Rho-kinase. Free Radic. Biol. Med. 41 (2006) 942-949
23. Morrow J.D., Awad J.A., Boss H.J., Blair I.A., and Roberts L.J. Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proc. Natl. Acad. Sci. USA 89 (1992) 10721-10725
24. Stafforini D.M., Sheller J.R., Blackwell T.S., Sapirstein A., Yull F.E., McIntyre T.M., et al. Release of free F2-isoprostanes from esterified phospholipids is catalyzed by intracellular and plasma platelet-activating factor acetylhydrolases. J. Biol. Chem. 281 (2006) 4616-4623
25. Milne G.L., and Morrow J.D. Isoprostanes and related compounds: update 2006. Antioxid. Redox Signal. 8 (2006) 1379-1384
26. Milne G.L., Yin H., and Morrow J.D. Human biochemistry of the isoprostane pathway. J. Biol. Chem. 283 (2008) 15533-15537
27. Musiek E.S., Yin H., Milne G.L., and Morrow J.D. Recent advances in the biochemistry and clinical relevance of the isoprostane pathway. Lipids 40 (2005) 987-994
28. Chen W., Pawelek T.R., and Kulmacz R.J. Hydroperoxide dependence and cooperative cyclooxygenase kinetics in prostaglandin H synthase-1 and -2. J. Biol. Chem. 274 (1999) 20301-20306
29. Chen Y., Morrow J.D., and Roberts L.J. Formation of reactive cyclopentenone compounds in vivo as products of the isoprostane pathway. J. Biol. Chem. 274 (1999) 10863-10868
30. Taber D.F., Morrow J.D., and Roberts L.J. A nomenclature system for the isoprostanes. Prostaglandins 53 (1997) 63-67
31. Rokach J., Khanapure S.P., Hwang S.W., Adiyaman M., Lawson J.A., and FitzGerald G.A. Nomenclature of isoprostanes: a proposal. Prostaglandins 54 (1997) 853-873
32. Yin H., Brooks J.D., Gao L., Porter N.A., and Morrow J.D. Identification of novel autoxidation products of the omega-3 fatty acid eicosapentaenoic acid in vitro and in vivo. J. Biol. Chem. 282 (2007) 29890-29901
33. Gao L., Yin H., Milne G.L., Porter N.A., and Morrow J.D. Formation of F-ring isoprostane-like compounds (F3-isoprostanes) in vivo from eicosapentaenoic acid. J. Biol. Chem. 281 (2006) 14092-14099
34. Brooks J.D., Milne G.L., Yin H., Sanchez S.C., Porter N.A., and Morrow J.D. Formation of highly reactive cyclopentenone isoprostane compounds (A3/J3-isoprostanes) in vivo from eicosapentaenoic acid. J. Biol. Chem. 283 (2008) 12043-12055
35. Brame C.J., Boutaud O., Davies S.S., Yang T., Oates J.A., Roden D., et al. Modification of proteins by isoketal-containing oxidized phospholipids. J. Biol. Chem. 279 (2004) 13447-13451
36. Brame C.J., Salomon R.G., Morrow J.D., and Roberts L.J. Identification of extremely reactive gamma-ketoaldehydes (isolevuglandins) as products of the isoprostane pathway and characterization of their lysyl protein adducts. J. Biol. Chem. 274 (1999) 13139-13146
37. Bernoud-Hubac N., Alam D.A., Lefils J., Davies S.S., Amarnath V., Guichardant M., et al. Low concentrations of reactive gamma-ketoaldehydes prime thromboxane-dependent human platelet aggregation via p38-MAPK activation. Biochim. Biophys. Acta 1791 (2009) 307-313
38. Davies S.S., Amarnath V., Montine K.S., Bernoud-Hubac N., Boutaud O., Montine T.J., et al. Effects of reactive gamma-ketoaldehydes formed by the isoprostane pathway (isoketals) and cyclooxygenase pathway (levuglandins) on proteasome function. FASEB J. 16 (2002) 715-717
39. Roberts L.J., Salomon R.G., Morrow J.D., and Brame C.J. New developments in the isoprostane pathway: identification of novel highly reactive gamma-ketoaldehydes (isolevuglandins) and characterization of their protein adducts. FASEB J. 13 (1999) 1157-1168
40. Boyden P.A., Davies S.S., Viswanathan P.C., Amarnath V., Balser J.R., and Roberts L.J. Potential role of isoketals formed via the isoprostane pathway of lipid peroxidation in ischemic arrhythmias. J. Cardiovasc. Pharmacol. 50 (2007) 480-486
41. Fessel J.P., Porter N.A., Moore K.P., Sheller J.R., and Roberts L.J. Discovery of lipid peroxidation products formed in vivo with a substituted tetrahydrofuran ring (isofurans) that are favored by increased oxygen tension. Proc. Natl. Acad. Sci. USA 99 (2002) 16713-16718
42. Fessel J.P., and Jackson R.L. Isofurans: novel products of lipid peroxidation that define the occurrence of oxidant injury in settings of elevated oxygen tension. Antioxid. Redox Signal. 7 (2005) 202-209
43. Kadiiska M.B., Gladen B.C., Baird D.D., Germolec D., Graham L.B., Parker C.E., et al. Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning?. Free Radic. Biol. Med. 38 (2005) 698-710
44. Milne G.L., Yin H., Brooks J.D., Sanchez S., Jackson R.L., and Morrow J.D. Quantification of F2-isoprostanes in biological fluids and tissues as a measure of oxidant stress. Methods Enzymol. 433 (2007) 113-126
45. Schweer H., Watzer B., Seyberth H.W., and Nusing R.M. Improved quantification of 8-epi-prostaglandin F2 alpha and F2-isoprostanes by gas chromatography/triple-stage quadrupole mass spectrometry: partial cyclooxygenase-dependent formation of 8-epi-prostaglandin F2 alpha in humans. J. Mass Spectrom. 32 (1997) 1362-1370
46. Roberts L.J., Moore K.P., Zackert W.E., Oates J.A., and Morrow J.D. Identification of the major urinary metabolite of the F2-isoprostane 8-iso-prostaglandin F2alpha in humans. J. Biol. Chem. 271 (1996) 20617-20620
47. Signore C., Aros S., Morrow J.D., Troendle J., Conley M.R., Flanigan E.Y., et al. Markers of oxidative stress and systemic vasoconstriction in pregnant women drinking > or =48 g of alcohol per day. Alcohol. Clin. Exp. Res. 32 (2008) 1893-1898
48. Cracowski J.L., and Durand T. Cardiovascular pharmacology and physiology of the isoprostanes. Fundam. Clin. Pharmacol. 20 (2006) 417-427
49. Janssen L.J. Isoprostanes and lung vascular pathology. Am. J. Respir. Cell Mol. Biol 39 (2008) 383-389
50. Morrow J.D., Zackert W.E., Yang J.P., Kurhts E.H., Callewaert D., Dworski R., et al. Quantification of the major urinary metabolite of 15-F2t-isoprostane (8-iso-PGF2alpha) by a stable isotope dilution mass spectrometric assay. Anal. Biochem. 269 (1999) 326-331
51. Sinzinger H., Oguogho A., and Kaliman J. Isoprostane 8-epi-prostaglandin F2 alpha is a potent contractor of human peripheral lymphatics. Lymphology 30 (1997) 155-159
52. Oguogho A., Kaliman J., and Sinzinger H. Levels of eicosanoids (6-oxo-PGF1 alpha and 8-epi-PGF2 alpha) in human and porcine lymphatics and lymph. Lymphology 31 (1998) 186-189
53. Janssen L.J., Premji M., Netherton S., Catalli A., Cox G., Keshavjee S., et al. Excitatory and inhibitory actions of isoprostanes in human and canine airway smooth muscle. J. Pharmacol. Exp. Ther. 295 (2000) 506-511
54. Sametz W., Hummer K., Butter M., Wintersteiger R., and Juan H. Formation of 8-iso-PGF(2alpha) and thromboxane A(2) by stimulation with several activators of phospholipase A(2) in the isolated human umbilical vein. Br. J. Pharmacol. 131 (2000) 145-151
55. Crankshaw D. Effects of the isoprostane, 8-epi-prostaglandin F2 alpha, on the contractility of the human myometrium in vitro. Eur. J. Pharmacol. 285 (1995) 151-158
56. Hou X., Roberts L.J., Taber D.F., Morrow J.D., Kanai K., Gobeil Jr. F., et al. 2,3-Dinor-5,6-dihydro-15-F(2t)-isoprostane: a bioactive prostanoid metabolite. Am. J. Physiol., Regul. Integr. Comp. Physiol. 281 (2001) R391-R400
57. Hou X., Roberts L.J., Gobeil Jr. F., Taber D., Kanai K., Abran D., et al. Isomer-specific contractile effects of a series of synthetic f2-isoprostanes on retinal and cerebral microvasculature. Free Radic. Biol. Med. 6 (2004) 163-172
58. Gonzalez-Luis G., Perez-Vizcaino F., Garcia-Munoz F., de Mey J.G., Blanco C.E., and Villamor E. Age-related differences in vasoconstrictor responses to isoprostanes in piglet pulmonary and mesenteric vascular smooth muscle. Pediatr. Res. 57 (2005) 845-852
59. Janssen L.J., and Tazzeo T. Involvement of TP and EP3 receptors in vasoconstrictor responses to isoprostanes in pulmonary vasculature. J. Pharmacol. Exp. Ther. 301 (2002) 1060-1066
60. Janssen L.J. Isoprostanes: an overview and putative roles in pulmonary pathophysiology. Am. J. Physiol., Lung Cell Mol. Physiol. 280 (2001) L1067-L1082
61. Jourdan K.B., Evans T.W., Curzen N.P., and Mitchell J.A. Evidence for a dilator function of 8-iso prostaglandin F2 alpha in rat pulmonary artery. Br. J. Pharmacol. 120 (1997) 1280-1285
62. Zhang Y., Pertens E., and Janssen L.J. 8-isoprostaglandin E(2) activates Ca(2+)-dependent K(+) current via cyclic AMP signaling pathway in murine renal artery. Eur. J. Pharmacol. 520 (2005) 22-28
63. Zhang Y., Tazzeo T., Hirota S., and Janssen L.J. Vasodilatory and electrophysiological actions of 8-iso-prostaglandin E2 in porcine coronary artery. J. Pharmacol. Exp. Ther. 305 (2003) 1054-1060
64. Clarke D.L., Belvisi M.G., Hardaker E., Newton R., and Giembycz M.A. E-ring 8-isoprostanes are agonists at EP2- and EP4-prostanoid receptors on human airway smooth muscle cells and regulate the release of colony-stimulating factors by activating cAMP-dependent protein kinase. Mol. Pharmacol. 67 (2005) 383-393
65. Kumar A., Kingdon E., and Norman J. The isoprostane 8-iso-PGF2alpha suppresses monocyte adhesion to human microvascular endothelial cells via two independent mechanisms. FASEB J. 19 (2005) 443-445
66. Zanoni G., Porta A., Castronovo F., and Vidari G. First total synthesis of JS isoprostane. J. Org. Chem 68 (2003) 6005-6010
67. Zanoni G., Porta A., and Vidari G. First total synthesis of A(2) isoprostane. J. Org. Chem. 67 (2002) 4346-4351
68. Milne G.L., Musiek E.S., and Morrow J.D. The cyclopentenone (A2/J2) isoprostanes-unique, highly reactive products of arachidonate peroxidation. Antioxid. Redox Signal. 7 (2005) 210-220
69. Musiek E.S., Breeding R.S., Milne G.L., Zanoni G., Morrow J.D., and McLaughlin B. Cyclopentenone isoprostanes are novel bioactive products of lipid oxidation which enhance neurodegeneration. J. Neurochem. 97 (2006) 1301-1313
70. Minuz P., Patrignani P., Gaino S., Degan M., Menapace L., Tommasoli R., et al. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation 106 (2002) 2800-2805
71. Hoeldtke R.D., Bryner K.D., McNeill D.R., Warehime S.S., Van D.K., and Hobbs G. Oxidative stress and insulin requirements in patients with recent-onset type 1 diabetes. J. Clin. Endocrinol. Metab. 88 (2003) 1624-1628
72. Davi G., Chiarelli F., Santilli F., Pomilio M., Vigneri S., Falco A., et al. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. Circulation 107 (2003) 3199-3203
73. Kauffman L.D., Sokol R.J., Jones R.H., Awad J.A., Rewers M.J., and Norris J.M. Urinary F2-isoprostanes in young healthy children at risk for type 1 diabetes mellitus. Free Radic. Biol. Med. 35 (2003) 551-557
74. Desco M.C., Asensi M., Marquez R., Martinez-Valls J., Vento M., Pallardo F.V., et al. Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol. Diabetes 51 (2002) 1118-1124
75. Martino F., Loffredo L., Carnevale R., Sanguigni V., Martino E., Catasca E., et al. Oxidative stress is associated with arterial dysfunction and enhanced intima-media thickness in children with hypercholesterolemia: the potential role of nicotinamide-adenine dinucleotide phosphate oxidase. Pediatrics 122 (2008) e648-e655
76. Gross M., Steffes M., Jacobs Jr. D.R., Yu X., Lewis L., Lewis C.E., et al. Plasma F2-isoprostanes and coronary artery calcification: the CARDIA Study. Clin. Chem. 51 (2005) 125-131
77. Cracowski J.L., Cracowski C., Bessard G., Pepin J.L., Bessard J., Schwebel C., et al. Increased lipid peroxidation in patients with pulmonary hypertension. Am. J. Respir. Crit. Care Med. 164 (2001) 1038-1042
78. Robbins I.M., Morrow J.D., and Christman B.W. Oxidant stress but not thromboxane decreases with epoprostenol therapy. Free Radic. Biol. Med. 38 (2005) 568-574
79. Back E.I., Frindt C., Nohr D., Frank J., Ziebach R., Stern M., et al. Antioxidant deficiency in cystic fibrosis: when is the right time to take action?. Am. J. Clin. Nutr. 80 (2004) 374-384
80. Wood L.G., Fitzgerald D.A., Gibson P.G., Cooper D.M., and Garg M.L. Increased plasma fatty acid concentrations after respiratory exacerbations are associated with elevated oxidative stress in cystic fibrosis patients. Am. J. Clin. Nutr. 75 (2002) 668-675
81. Wood L.G., Fitzgerald D.A., Gibson P.G., Cooper D.M., Collins C.E., and Garg M.L. Oxidative stress in cystic fibrosis: dietary and metabolic factor. J. Am. Coll. Nutr. 20 (2001) 157-165
82. Collins C.E., Quaggiotto P., Wood L., O'Loughlin E.V., Henry R.L., and Garg M.L. Elevated plasma levels of F2 alpha isoprostane in cystic fibrosis. Lipids 34 (1999) 551-556
83. Ciabattoni G., Davi G., Collura M., Iapichino L., Pardo F., Ganci A., et al. In vivo lipid peroxidation and platelet activation in cystic fibrosis. Am. J. Respir. Crit. Care Med. 162 (2000) 1195-1201
84. Zanconato S., Carraro S., Corradi M., Alinovi R., Pasquale M.F., Piacentini G., et al. Leukotrienes and 8-isoprostane in exhaled breath condensate of children with stable and unstable asthma. J. Allergy Clin. Immunol. 113 (2004) 257-263
85. Baraldi E., Ghiro L., Piovan V., Carraro S., Ciabattoni G., Barnes P.J., et al. Increased exhaled 8-isoprostane in childhood asthma. Chest 124 (2003) 25-31
86. Baraldi E., Carraro S., Alinovi R., Pesci A., Ghiro L., Bodini A., et al. Cysteinyl leukotrienes and 8-isoprostane in exhaled breath condensate of children with asthma exacerbations. Thorax 58 (2003) 505-509
87. Bodini A., Peroni D., Vicentini L., Loiacono A., Baraldi E., Ghiro L., et al. Exhaled breath condensate eicosanoids and sputum eosinophils in asthmatic children: a pilot study. Pediatr. Allergy Immunol. 15 (2004) 26-31
88. Wood L.G., Fitzgerald D.A., Gibson P.G., Cooper D.M., and Garg M.L. Lipid peroxidation as determined by plasma isoprostanes is related to disease severity in mild asthma. Lipids 35 (2000) 967-974
89. Dworski R., Murray J.J., Roberts L.J., Oates J.A., Morrow J.D., Fisher L., et al. Allergen-induced synthesis of F(2)-isoprostanes in atopic asthmatics. Evidence for oxidant stress. Am. J. Respir. Crit. Care Med. 160 (1999) 1947-1951
90. Dworski R., Roberts L.J., Murray J.J., Morrow J.D., Hartert T.V., and Sheller J.R. Assessment of oxidant stress in allergic asthma by measurement of the major urinary metabolite of F2-isoprostane, 15-F2t-IsoP (8-iso-PGF2alpha). Clin. Exp. Allergy 31 (2001) 387-390
91. Kawikova I., Barnes P.J., Takahashi T., Tadjkarimi S., Yacoub M.H., and Belvisi M.G. 8-Epi-PGF2 alpha, a novel noncyclooxygenase-derived prostaglandin, constricts airways in vitro. Am. J. Respir. Crit. Care Med. 153 (1996) 590-596
92. bou-Raya A., el-Hallous D., and Fayed H. 8-Isoprostaglandin F2 alpha: a potential index of lipid peroxidation in systemic lupus erythematosus. Clin. Invest. Med. 27 (2004) 306-311
93. Soep J.B., Mietus-Snyder M., Malloy M.J., Witztum J.L., and von S.E. Assessment of atherosclerotic risk factors and endothelial function in children and young adults with pediatric-onset systemic lupus erythematosus. Arthritis Rheum. 51 (2004) 451-457
94. Greco A., Minghetti L., Puopolo M., Cannoni S., Romano S., Pozzilli C., et al. Cerebrospinal fluid isoprostanes are not related to inflammatory activity in relapsing-remitting multiple sclerosis. J. Neurol. Sci. 224 (2004) 23-27
95. Cracowski J.L., Bonaz B., Bessard G., Bessard J., Anglade C., and Fournet J. Increased urinary F2-isoprostanes in patients with Crohn's disease. Am. J. Gastroenterol. 97 (2002) 99-103
96. Martinuzzo M.E., Forastiero R.R., Kordich L., and Carreras L.O. Increased lipid peroxidation correlates with platelet activation but not with markers of endothelial cell and blood coagulation activation in patients with antiphospholipid antibodies. Br. J. Haematol. 114 (2001) 845-851
97. Kim K.M., Paeng K.J., Hahm J.R., Kim D.R., and Chung B.C. Elevated urinary 8-isoprostaglandin F(2alpha) in females with Graves' hyperthyroidism. Prostaglandins Leukot. Essent. Fatty Acids 71 (2004) 143-147
98. Grosso S., Perrone S., Longini M., Bruno C., Minetti C., Gazzolo D., et al. Isoprostanes in dystrophinopathy: Evidence of increased oxidative stress. Brain Dev. 30 (2008) 391-395
99. Akohoue S.A., Shankar S., Milne G.L., Morrow J., Chen K.Y., Ajayi W.U., et al. Energy expenditure, inflammation, and oxidative stress in steady-state adolescents with sickle cell anemia. Pediatr. Res. 61 (2007) 233-238
100. Bayir H., Kagan V.E., Tyurina Y.Y., Tyurin V., Ruppel R.A., Adelson P.D., et al. Assessment of antioxidant reserves and oxidative stress in cerebrospinal fluid after severe traumatic brain injury in infants and children. Pediatr. Res. 51 (2002) 571-578
101. Braekke K., Harsem N.K., and Staff A.C. Oxidative stress and antioxidant status in fetal circulation in preeclampsia. Pediatr. Res. 60 (2006) 560-564
102. Hermenegildo C., Garcia-Martinez M.C., Tarin J.J., and Cano A. Estradiol reduces F2alpha-isoprostane production in cultured human endothelial cells. Am. J. Physiol., Heart Circ. Physiol. 283 (2002) H2644-H2649
103. Walsh S.W., Vaughan J.E., Wang Y., and Roberts L.J. Placental isoprostane is significantly increased in preeclampsia. FASEB J. 14 (2000) 1289-1296
104. Staff A.C., Halvorsen B., Ranheim T., and Henriksen T. Elevated level of free 8-iso-prostaglandin F2alpha in the decidua basalis of women with preeclampsia. Am. J. Obstet. Gynecol. 181 (1999) 1211-1215
105. Mandang S., Manuelpillai U., and Wallace E.M. Oxidative stress increases placental and endothelial cell activin A secretion. J. Endocrinol. 192 (2007) 485-493
106. Davidge S.T. Oxidative stress and altered endothelial cell function in preeclampsia. Semin. Reprod. Endocrinol. 16 (1998) 65-73
107. Nash P., Wentzel P., Lindeberg S., Naessen T., Jansson L., Olovsson M., et al. Placental dysfunction in Suramin-treated rats-a new model for pre-eclampsia. Placenta 26 (2005) 410-418
108. Cederberg J., Basu S., and Eriksson U.J. Increased rate of lipid peroxidation and protein carbonylation in experimental diabetic pregnancy. Diabetologia 44 (2001) 766-774
109. Gerber R.T., Holemans K., O'Brien-Coker I., Mallet A.I., van B.R., Van Assche F.A., et al. Increase of the isoprostane 8-isoprostaglandin f2alpha in maternal and fetal blood of rats with streptozotocin-induced diabetes: evidence of lipid peroxidation. Am. J. Obstet. Gynecol. 183 (2000) 1035-1040
110. Zabihi S., Wentzel P., and Eriksson U.J. Maternal blood glucose levels determine the severity of diabetic embryopathy in mice with different expression of copper-zinc superoxide dismutase (CuZnSOD). Toxicol. Sci. 105 (2008) 166-172
111. Franco M.C., Kawamoto E.M., Gorjao R., Rastelli V.M., Curi R., Scavone C., et al. Biomarkers of oxidative stress and antioxidant status in children born small for gestational age: evidence of lipid peroxidation. Pediatr. Res. 62 (2007) 204-208
112. Longini M., Perrone S., Kenanidis A., Vezzosi P., Marzocchi B., Petraglia F., et al. Isoprostanes in amniotic fluid: a predictive marker for fetal growth restriction in pregnancy. Free Radic. Biol. Med. 38 (2005) 1537-1541
113. Obwegeser R., Oguogho A., Ulm M., Berghammer P., and Sinzinger H. Maternal cigarette smoking increases F2-isoprostanes and reduces prostacyclin and nitric oxide in umbilical vessels. Prostaglandins Other Lipid Mediat. 57 (1999) 269-279
114. Perrone S., Longini M., Bellieni C.V., Centini G., Kenanidis A., De M.L., et al. Early oxidative stress in amniotic fluid of pregnancies with Down syndrome. Clin. Biochem. 40 (2007) 177-180
115. Longini M., Perrone S., Vezzosi P., Marzocchi B., Kenanidis A., Centini G., et al. Association between oxidative stress in pregnancy and preterm premature rupture of membranes. Clin. Biochem. 40 (2007) 793-797
116. Qin Y., Wang C.C., Kuhn H., Rathmann J., Pang C.P., and Rogers M.S. Determinants of umbilical cord arterial 8-iso-prostaglandin F2alpha concentrations. BJOG 107 (2000) 973-981
117. Barden A.E., Mori T.A., Dunstan J.A., Taylor A.L., Thornton C.A., Croft K.D., et al. Fish oil supplementation in pregnancy lowers F2-isoprostanes in neonates at high risk of atopy. Free Radic. Res. 38 (2004) 233-239
118. Rietjens S.J., Beelen M., Koopman R., VAN Loon L.J., Bast A., and Haenen G.R. A single session of resistance exercise induces oxidative damage in untrained men. Med. Sci. Sports Exerc. 39 (2007) 2145-2151
119. Rodriguez M.C., MacDonald J.R., Mahoney D.J., Parise G., Beal M.F., and Tarnopolsky M.A. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve 35 (2007) 235-242
120. Welin A.K., Svedin P., Lapatto R., Sultan B., Hagberg H., Gressens P., et al. Melatonin reduces inflammation and cell death in white matter in the mid-gestation fetal sheep following umbilical cord occlusion. Pediatr. Res. 61 (2007) 153-158
121. Daray F.M., Minvielle A.I., Puppo S., and Rothlin R.P. Vasoconstrictor effects of 8-iso-prostaglandin E2 and 8-iso-prostaglandin F(2alpha) on human umbilical vein. Eur. J. Pharmacol. 499 (2004) 189-195
122. Daray F.M., Colombo J.R., Kibrik J.R., Errasti A.E., Pelorosso F.G., Nowak W., et al. Involvement of endothelial thromboxane A2 in the vasoconstrictor response induced by 15-E2t-isoprostane in isolated human umbilical vein. Naunyn Schmiedebergs Arch. Pharmacol. 373 (2006) 367-375
123. Oliveira L., Stallwood N.A., and Crankshaw D.J. Effects of some isoprostanes on the human umbilical artery in vitro. Br. J. Pharmacol. 129 (2000) 509-514
124. Friel A.M., Sexton D.J., O'reilly M.W., Smith T.J., and Morrison J.J. Rho A/Rho kinase: human umbilical artery mRNA expression in normal and pre eclamptic pregnancies and functional role in isoprostane-induced vasoconstriction. Reproduction 132 (2006) 169-176
125. Abman S.H. Recent advances in the pathogenesis and treatment of persistent pulmonary hypertension of the newborn. Neonatology 91 (2007) 283-290
126. Gonzalez-Luis G., Cogolludo A., Moreno L., Lodi F., Tamargo J., Perez-Vizcaino F., et al. Relaxant effects of the soluble guanylate cyclase activator and NO sensitizer YC-1 in piglet pulmonary arteries. Biol. Neonate 90 (2006) 66-72
127. Moreno L., Losada B., Cogolludo A., Lodi F., Lugnier C., Villamor E., et al. Postnatal maturation of phosphodiesterase 5 (PDE5) in piglet pulmonary arteries: activity, expression, effects of PDE5 inhibitors, and role of the nitric oxide/cyclic GMP pathway. Pediatr. Res. 56 (2004) 563-570
128. Moreno L., Gonzalez-Luis G., Cogolludo A., Lodi F., Lopez-Farre A., Tamargo J., et al. Soluble guanylyl cyclase during postnatal porcine pulmonary maturation. Am. J. Physiol., Lung Cell Mol. Physiol. 288 (2005) L125-L130
129. Villamor E., Perez-Vizcaino F., Cogolludo A.L., Conde-Oviedo J., Zaragoza-Arnaez F., Lopez-Lopez J.G., et al. Relaxant effects of carbon monoxide compared with nitric oxide in pulmonary and systemic vessels of newborn piglets. Pediatr. Res. 48 (2000) 546-553
130. Villamor E., Degraeuwe P.L., de Mey J.G., and Blanco C.E. Vascular reactivity of pulmonary arteries from premature lambs subjected to liquid ventilation. Biol. Neonate 84 (2003) 172-178
131. Belik J., Jankov R.P., Pan J., Yi M., Pace-Asciak C.R., and Tanswell A.K. Effect of 8-isoprostaglandin F2alpha on the newborn rat pulmonary arterial muscle and endothelium. J. Appl. Physiol. 95 (2003) 1979-1985
132. Gonzalez-Luis G., Perez-Vizcaino F., Blanco C.E., and Villamor E. Age-related changes in isoprostane-mediated relaxation of piglet blood vessels. Front. Biosci. E2 (2010) 369-379
133. Belik J., Kerc E., and Pato M.D. Rat pulmonary arterial smooth muscle myosin light chain kinase and phosphatase activities decrease with age. Am. J. Physiol., Lung Cell Mol. Physiol 290 (2006) L509-L516
134. Truog W.E., Norberg M., and Thibeault D.W. Effects of 8-epi-prostaglandin F2 alpha and U46,619 on pulmonary hemodynamics in piglets. Biol. Neonate 71 (1997) 306-316
135. Signorini C., Perrone S., Sgherri C., Ciccoli L., Buonocore G., Leoncini S., et al. Plasma esterified F2-isoprostanes and oxidative stress in newborns: role of nonprotein-bound iron. Pediatr. Res. 63 (2008) 287-291
136. Rossi V., Leoncini S., Signorini C., Buonocore G., Paffetti P., Tanganelli D., et al. Oxidative stress and autologous immunoglobulin G binding to band 3 dimers in newborn erythrocytes. Free Radic. Biol. Med. 40 (2006) 907-915
137. Back S.A., Riddle A., and McClure M.M. Maturation-dependent vulnerability of perinatal white matter in premature birth. Stroke 38 (2007) 724-730
138. Back S.A., Luo N.L., Mallinson R.A., O'Malley J.P., Wallen L.D., Frei B., et al. Selective vulnerability of preterm white matter to oxidative damage defined by F2-isoprostanes. Ann. Neurol. 58 (2005) 108-120
139. Inder T., Mocatta T., Darlow B., Spencer C., Volpe J.J., and Winterbourn C. Elevated free radical products in the cerebrospinal fluid of VLBW infants with cerebral white matter injury. Pediatr. Res. 52 (2002) 213-218
140. Calamandrei G., Venerosi A.P., Valanzano A., de Berardinis M.A., Greco A., Puopolo M., et al. Increased brain levels of F2-isoprostane are an early marker of behavioral sequels in a rat model of global perinatal asphyxia. Pediatr. Res. 55 (2004) 85-92
141. Hou X., Gobeil Jr. F., Peri K., Speranza G., Marrache A.M., Lachapelle P., et al. Augmented vasoconstriction and thromboxane formation by 15-F(2t)-isoprostane (8-iso-prostaglandin F(2alpha)) in immature pig periventricular brain microvessels. Stroke 31 (2000) 516-524
142. Brault S., Martinez-Bermudez A.K., Roberts J., Cui Q.L., Fragoso G., Hemdan S., et al. Cytotoxicity of the E(2)-isoprostane 15-E(2t)-IsoP on oligodendrocyte progenitors. Free Radic. Biol. Med. 37 (2004) 358-366
143. Brault S., Martinez-Bermudez A.K., Marrache A.M., Gobeil Jr. F., Hou X., Beauchamp M., et al. Selective neuromicrovascular endothelial cell death by 8-Iso-prostaglandin F2alpha: possible role in ischemic brain injury. Stroke 34 (2003) 776-782
144. Greco A., and Minghetti L. Isoprostanes as biomarkers and mediators of oxidative injury in infant and adult central nervous system diseases. Curr. Neurovasc. Res. 1 (2004) 341-354
145. Roberts L.J., Montine T.J., Markesbery W.R., Tapper A.R., Hardy P., Chemtob S., et al. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J. Biol. Chem. 273 (1998) 13605-13612
146. Bland R.D. Neonatal chronic lung disease in the post-surfactant era. Biol. Neonate 88 (2005) 181-191
147. Saugstad O.D. Bronchopulmonary dysplasia-oxidative stress and antioxidants. Semin. Neonatol. 8 (2003) 39-49
148. Reuter S.D., O'Donovan D.J., Hegemier S.E., Smith E.O., Heird W.C., and Fernandes C.J. Urinary F2-isoprostanes are poor prognostic indicators for the development of bronchopulmonary dysplasia. J. Perinatol. 27 (2007) 303-306
149. Goil S., Truog W.E., Barnes C., Norberg M., Rezaiekhaligh M., and Thibeault D. Eight-epi-PGF2alpha: a possible marker of lipid peroxidation in term infants with severe pulmonary disease. J. Pediatr. 132 (1998) 349-351
150. Vento M., Roberts J.L., Izquierdo I., Arruza A., Escrig R., Villar G., et al. Monitorization of hypo-or-hyperoxia derived oxidative stress in extremely low birthweight (ELBW) infants using urinary F2-isoprostanes and isofuranes. E-PAS2008 (2009) 5851
151. Lakshminrusimha S., Russell J.A., Wedgwood S., Gugino S.F., Kazzaz J.A., Davis J.M., et al. Superoxide dismutase improves oxygenation and reduces oxidation in neonatal pulmonary hypertension. Am. J. Respir. Crit. Care Med. 174 (2006) 1370-1377
152. Ozaki N., Beharry K., Nishihara K.C., Akmal Y., Ang J.G., and Modanlou H.D. Differential regulation of prostacyclin and thromboxane by
153. Tanswell A.K., and Jankov R.P. Bronchopulmonary dysplasia: one disease or two?. Am. J. Respir. Crit. Care Med. 167 (2003) 1-2
154. 2 toxicity in cultured fetal rat distal lung epithelial cells. Free Radic. Biol. Med. 26 (1999) 1357-1368
155. Jankov R.P., Luo X., Cabacungan J., Belcastro R., Frndova H., Lye S.J., et al. Endothelin-1 and O2-mediated pulmonary hypertension in neonatal rats: a role for products of lipid peroxidation. Pediatr. Res. 48 (2000) 289-298
156. Jankov R.P., Luo X., Belcastro R., Copland I., Frndova H., Lye S.J., et al. Gadolinium chloride inhibits pulmonary macrophage influx and prevents O(2)-induced pulmonary hypertension in the neonatal rat. Pediatr. Res. 50 (2001) 172-183
157. Jankov R.P., Belcastro R., Ovcina E., Lee J., Massaeli H., Lye S.J., et al. Thromboxane A(2) receptors mediate pulmonary hypertension in 60% oxygen-exposed newborn rats by a cyclooxygenase-independent mechanism. Am. J. Respir. Crit. Care Med. 166 (2002) 208-214
158. Belik J., Jankov R.P., Pan J., Yi M., Chaudhry I., and Tanswell A.K. Chronic O2 exposure in the newborn rat results in decreased pulmonary arterial nitric oxide release and altered smooth muscle response to isoprostane. J. Appl. Physiol. 96 (2004) 725-730
159. McNamara P.J., Murthy P., Kantores C., Teixeira L., Engelberts D., van V.T., et al. Acute vasodilator effects of Rho-kinase inhibitors in neonatal rats with pulmonary hypertension unresponsive to nitric oxide. Am. J. Physiol. 294 (2008) L205-L213
160. Jankov R.P., Kantores C., Pan J., and Belik J. Contribution of xanthine oxidase-derived superoxide to chronic hypoxic pulmonary hypertension in neonatal rats. Am. J. Physiol., Lung Cell Mol. Physiol 294 (2008) L233-L245
161. Lahaie I., Hardy P., Hou X., Hassessian H., Asselin P., Lachapelle P., et al. A novel mechanism for vasoconstrictor action of 8-isoprostaglandin F2 alpha on retinal vessels. Am. J. Physiol. 274 (1998) R1406-R1416
162. Beauchamp M.H., Martinez-Bermudez A.K., Gobeil Jr. F., Marrache A.M., Hou X., Speranza G., et al. Role of thromboxane in retinal microvascular degeneration in oxygen-induced retinopathy. J. Appl. Physiol. 90 (2001) 2279-2288
163. Takahashi K., Nammour T.M., Fukunaga M., Ebert J., Morrow J.D., Roberts L.J., et al. Glomerular actions of a free radical-generated novel prostaglandin, 8-epi-prostaglandin F2 alpha, in the rat. Evidence for interaction with thromboxane A2 receptors. J. Clin. Invest. 90 (1992) 136-141
164. John G.W., and Valentin J.P. Analysis of the pulmonary hypertensive effects of the isoprostane derivative, 8-iso-PGF2alpha, in the rat. Br. J. Pharmacol. 122 (1997) 899-905
165. Kang K.H., Morrow J.D., Roberts L.J., Newman J.H., and Banerjee M. Airway and vascular effects of 8-epi-prostaglandin F2 alpha in isolated perfused rat lung. J. Appl. Physiol. 74 (1993) 460-465
166. Wagner R.S., Weare C., Jin N., Mohler E.R., and Rhoades R.A. Characterization of signal transduction events stimulated by 8-epi-prostaglandin(PG)F2 alpha in rat aortic rings. Prostaglandins 54 (1997) 581-599
167. Sametz W., Hennerbichler S., Glaser S., Wintersteiger R., and Juan H. Characterization of prostanoid receptors mediating actions of the isoprostanes, 8-iso-PGE(2) and 8-iso-PGF(2alpha), in some isolated smooth muscle preparations. Br. J. Pharmacol. 130 (2000) 1903-1910
168. Hoffman S.W., Moore S., and Ellis E.F. Isoprostanes: free radical-generated prostaglandins with constrictor effects on cerebral arterioles. Stroke 28 (1997) 844-849
169. Marley R., Harry D., Anand R., Fernando B., Davies S., and Moore K. 8-Isoprostaglandin F2 alpha, a product of lipid peroxidation, increases portal pressure in normal and cirrhotic rats. Gastroenterology 112 (1997) 208-213
170. Audoly L.P., Rocca B., Fabre J.E., Koller B.H., Thomas D., Loeb A.L., et al. Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo. Circulation 101 (2000) 2833-2840
171. Banerjee M., Kang K.H., Morrow J.D., Roberts L.J., and Newman J.H. Effects of a novel prostaglandin, 8-epi-PGF2 alpha, in rabbit lung in situ. Am. J. Physiol. 263 (1992) H660-H663
172. Sametz W., Grobuschek T., Hammer-Kogler S., Juan H., and Wintersteiger R. Influence of isoprostanes on vasoconstrictor effects of noradrenaline and angiotensin II. Eur. J. Pharmacol. 378 (1999) 47-55
173. Mobert J., Becker B.F., Zahler S., and Gerlach E. Hemodynamic effects of isoprostanes (8-iso-prostaglandin F2alpha and E2) in isolated guinea pig hearts. J. Cardiovasc. Pharmacol. 29 (1997) 789-794
174. Miller J.M., Brown J.N., and Schacht J. 8-iso-prostaglandin F(2alpha), a product of noise exposure, reduces inner ear blood flow. Audiol. Neuro-otol. 8 (2003) 207-221
175. Kromer B.M., and Tippins J.R. Coronary artery constriction by the isoprostane 8-epi prostaglandin F2 alpha. Br. J. Pharmacol. 119 (1996) 1276-1280
176. Mohler E.R., Franklin M.T., and Adam L.P. Intracellular signaling by 8-epi-prostaglandin F2 alpha is mediated by thromboxane A2/prostaglandin endoperoxide receptors in porcine carotid arteries. Biochem. Biophys.Res. Commun. 225 (1996) 915-923
177. Wilson S.H., Best P.J., Lerman L.O., Holmes Jr. D.R., Richardson D.M., and Lerman A. Enhanced coronary vasoconstriction to oxidative stress product, 8-epi-prostaglandinF2 alpha, in experimental hypercholesterolemia. Cardiovasc. Res. 44 (1999) 601-607
178. Janssen L.J., Premji M., Netherton S., Coruzzi J., Lu-Chao H., and Cox P.G. Vasoconstrictor actions of isoprostanes via tyrosine kinase and Rho kinase in human and canine pulmonary vascular smooth muscles. Br. J. Pharmacol. 132 (2001) 127-134
179. Gardan B., Cracowski J.L., Sessa C., Hunt M., Stanke-Labesque F., Devillier P., et al. Vasoconstrictor effects of iso-prostaglandin F2alpha type-III (8-iso-prostaglandin F2alpha) on human saphenous veins. J. Cardiovasc. Pharmacol. 35 (2000) 729-734
180. Cracowski J.L., Stanke-Labesque F., Devillier P., Chavanon O., Hunt M., Souvignet C., et al. Human internal mammary artery contraction by isoprostaglandin f(2alpha) type-III [8-iso-prostaglandin F(2alpha)]. Eur. J. Pharmacol. 397 (2000) 161-168
181. Mueed I., Tazzeo T., Liu C., Pertens E., Zhang Y., Cybulski I., et al. Isoprostanes constrict human radial artery by stimulation of thromboxane receptors, Ca2+ release, and RhoA activation. J. Thorac. Cardiovasc. Surg. 135 (2008) 131-138
182. Friel A.M., Hynes P.G., Sexton D.J., Smith T.J., and Morrison J.J. Expression levels of mRNA for Rho A/Rho kinase and its role in isoprostane-induced vasoconstriction of human placental and maternal vessels. Reprod. Sci. 15 (2008) 179-188